Lord, Abbett & Co
JAZZ icon

Lord, Abbett & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History

Lord, Abbett & Co’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-240,426
Closed -$30.8M – 707
2019
Q3 		$30.8M Sell
240,426
-6,926
-3% -$928K 0.1% 321
2019
Q2 		$35.3M Sell
247,352
-21,620
-8% -$2.91M 0.11% 308
2019
Q1 		$38.5M Buy
268,972
+51,014
+23% +$6.65M 0.13% 259
2018
Q4 		$27M Buy
217,958
+180,447
+481% +$26.8M 0.1% 318
2018
Q3 		$6.31M Buy
37,511
+14,505
+63% +$2.49M 0.02% 701
2018
Q2 		$3.96M Buy
+23,006
New +$3.76M 0.01% 770
2014
Q1 		– Sell
-371,410
Closed -$47M – 1041
2013
Q4 		$47M Sell
371,410
-171,701
-32% -$17.8M 0.1% 279
2013
Q3 		$50M Buy
543,111
+112,107
+26% +$9.04M 0.12% 251
2013
Q2 		$29.6M Buy
+431,004
New +$26.3M 0.07% 417

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Lord, Abbett & Co's JAZZ Position: Q4 2019 in Review

Lord, Abbett & Co sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2019, closing a stake of 240,426 shares — an estimated $30.8M sold.

Lord, Abbett & Co first reported a position in JAZZ in Q2 2013 and held it in 9 quarters. The position peaked at $50M in Q3 2013. 446 funds tracked by Wall St. Rank hold JAZZ as of Q4 2019.

  • Lord, Abbett & Co reported no remaining Jazz Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Lord, Abbett & Co sold 240,426 Jazz Pharmaceuticals shares in Q4 2019, an estimated $30.8M.
  • Lord, Abbett & Co first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 9 quarters.
  • Lord, Abbett & Co's Jazz Pharmaceuticals position peaked at $50M in Q3 2013.
  • 446 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2019.

Based on Lord, Abbett & Co's 13F filing for Q4 2019, filed 14 Feb 2020.